Profile banner
Sam Clark, MD, PhD

Sam Clark, MD, PhD

Founder & CEO, Terran Biosciences; neuroscientist and inventor

New York, New York
fda
Favicon imageterranbiosciences.com
Favicon imageorcid.org
Favicon imagelinkedin.com

Summary

Founder and biotech operator focused on neuropsychiatry: Sam Clark founded Terran Biosciences in 2017 and leads the company as CEO, building a small, tech-enabled platform biotech that advances imaging software (NM-101), long-acting prodrug therapeutics (TerXT) and a drug design engine while managing licensing and partnerships. terranbiosciences+2
Scientist-inventor with formal clinical and research training: He holds MD and PhD degrees from Columbia (and an undergraduate degree from MIT), has authored peer-reviewed neuroscience work, and maintains an ORCID profile documenting research contributions and funded training. orcid+1
Active intellectual property and medicinal chemistry focus: Clark is named on numerous patent filings and granted patents focused on psychedelics, prodrugs, and CNS-active compositions (including MDMA, psilocybin forms, DMT prodrugs), indicating a major focus on innovative chemistry and regulatory strategies to broaden access to novel therapeutics. google+2
Translational focus on tools and therapeutics for neurological and psychiatric disease: Activities span diagnostic software (FDA-cleared NM-101) to late-stage therapeutic development (TerXT for schizophrenia) and partnerships with academic centers to translate CNS biomarkers into clinical workflows. businesswire+2

Work

Education

Projects

Writing

Realizing the Promise of Neuromelanin-Sensitive MRI (NM-MRI)

April 1, 2024

A long-form article discussing the potential clinical applications of neuromelanin-sensitive MRI, the benefits versus DaT-SPECT, and recent advances including harmonization methods and the NM-101 software platform.

Favicon imagemedcitynews.com

US Patent US 11,958,821 (granted) — New salts and polymorphs of MDMA (MDMA hemifumarate)

April 1, 2024

Granted US patent covering new salts/polymorphs of MDMA, pharmaceutical compositions using these forms, and methods of use (inventor: Sam Clark); positioned for potential regulatory strategies including 505(b)(2).

Favicon imagebusinesswire.com

WO2023283373A1 / related patent publications — MDMA and related psychedelics

January 1, 2023

Patent publication(s) describing derivatives, prodrugs and related compositions of MDMA and other psychedelic compounds with potential therapeutic uses; Sam Clark listed as inventor/assignee in filings.

Favicon imagepatents.google.com

Peer-reviewed neuroscience publications (selected)

Peer-reviewed research contributions in neuroscience (examples appear on ORCID and include Nature Communications and Neuropsychopharmacology articles where Samuel/Sam Clark is listed as a contributor).

Favicon imageorcid.org